Engineered T cells for Colorectal Cancer.
Immunotherapy
; : 1-12, 2024 Sep 04.
Article
de En
| MEDLINE
| ID: mdl-39229803
Colorectal cancer (CRC) is a significant cause of cancer cases and cancer-related deaths globally. Current treatments for CRC have limitations; hence, there is a need for new and innovative approaches. Recent progress in cancer research has led to the development of personalized targeted therapies and immunotherapies, that is, treatments that use the body's immune system to fight cancer. T cell-based therapy is a type of immunotherapy that has shown promising outcomes in cancer treatment. This therapy involves modifying a type of immune cell called T cells to specifically target cancer cells. In this review, the focus is on the landscape of engineered T cells as a potential option for the treatment of CRC, as well as their challenges and current advancements. Generally, additional research and clinical trials are needed to fully explore its safety and efficacy in improving patient outcomes.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Langue:
En
Journal:
Immunotherapy
Sujet du journal:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Année:
2024
Type de document:
Article
Pays d'affiliation:
Malaisie
Pays de publication:
Royaume-Uni